Tekla Capital Management

Founded 1986

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 38
Average round size
info
The average size of a deal this fund participated in
$57M
Portfolio companies 33
Rounds per year 1.09
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.13
Exits 15
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

The main office of represented VC is situated in the Boston. The company was established in North America in United States.

We also calculated 1 valuable employee in our database.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Tekla Capital Management, startups are often financed by Novartis Venture Fund, Domain Associates, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Sofinnova Investments, Redmile Group. In the next rounds fund is usually obtained by Sofinnova Investments, Life Sciences Partners, Ysios Capital.

The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. This Tekla Capital Management works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018.

Among the most popular portfolio startups of the fund, we may highlight Afferent Pharmaceuticals, Merus, CuraSen Therapeutics. We can highlight the next thriving fund investment areas, such as Medical, Health Care. The fund has exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Arbor Biotechnologies

Biopharma
Biotechnology
Life Science
$215M09 Nov 2021 Cambridge, Massachusetts, United States

Parthenon Therapeutics

Biotechnology
Life Science
Therapeutics
$65M03 Nov 2021 Cambridge, Massachusetts, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$80M21 Oct 2021 Dallas, Texas, United States

Aristea Therapeutics

Biotechnology
Medical
Pharmaceutical
$63M27 Jul 2021 San Diego, California, United States

BioTheryX

Biotechnology
Health Care
Medical
Therapeutics
$92M20 May 2021 Chappaqua, New York, United States

Oculis

Biotechnology
Health Care
Pharmaceutical
$57M04 May 2021 Iceland, Iceland

Pyxis Oncology

Biotechnology
Health Care
Pharmaceutical
$152M30 Mar 2021 Boston, Massachusetts, United States

VectivBio

Biotechnology
Health Care
Medical
$110M19 Oct 2020 Basel, Basel-City, Switzerland

Priothera

Biotechnology
Health Care
Medical
Pharmaceutical
$35M12 Oct 2020 County Dublin
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Aristea Therapeutics Closes $63M Series B Financing

– Aristea Therapeutics, a San Diego, CA-based clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, closed a $63m Series B financing.
– The round was led by Fidelity Management & Research Company, with participation from existing investor Novo Holdings A/S and new investors Arena Pharmaceuticals and funds managed by Tekla Capital Management.
– The company intends to use the funds to continue the build-out of its leadership team, the formation of new partnerships and the advancement of the development of its portfolio of immunology focused programs to address orphan diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Tekla Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: